Drug intelligence / Profile preview

Urocortin 3

Development stage: Phase 1
Lead developer: Janssen Pharmaceutical
Modality: Peptides
Administration: Intravenous

Overview

Urocortin 3 is a 38-41 amino acid peptide belonging to the corticotropin-releasing factor (CRF) family. It functions as a highly selective agonist for the CRF type 2 receptor (CRFR2). UCN3 plays important roles in glucose metabolism by stimulating insulin secretion from pancreatic β-cells, particularly under high glucose conditions. It also has significant cardiovascular effects, including vasodilation, reduced peripheral vascular resistance, and increased cardiac output. These properties make it a potential therapeutic candidate for heart failure and metabolic disorders.

Other names: stresscopin

Targets

CRHR2 (Corticotropin-releasing hormone receptor 2)

Beyond the preview

Go deeper on Urocortin 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urocortin 3.

Explore the full profile